Lumeda is a medical technology company focused on improving outcomes for patients diagnosed with non-small cell lung cancer (NSCLC). Our breakthrough light dosimetry product called DigiLum is designed to activate a photosensitizer drug and deliver Photodynamic Therapy (PDT) to reduce the recurrence of cancer and enhance antitumor immunity.
Lumeda was formed in 2019 by a management team with a track record of creating successful new ventures to respond to market needs. We are a multidisciplinary team of highly experienced professionals committed to introducing new adjuvant treatment modalities for cancer. We strive for technical excellence and work to the highest ethical standards.
Lumeda is targeting two thoracic indications for DigiLum. The first involves intraoperative use of DigiLum to reduce cancer recurrence following NSCLC tumor resection. The second involves the use of DigiLum for patients with unresectable tumors to elicit an antitumor response and help patients get maximum benefit from immunotherapy drugs.